The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kaibysheva V.O.

Pirogov Russian National Research Medical University;
Savelyeva City Clinical Hospital No. 31

Of particular concern

Authors:

Kaibysheva V.O.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2026;(1‑2): 60‑66

Read: 124 times

To cite this article:

Kaibysheva VO. Of particular concern. Non Nocere. New Therapeutic Journal. 2026;(1‑2):60‑66. (In Russ.)

References:

  1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-891.  https://doi.org/10.1056/NEJMoa1009638
  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-1151. https://doi.org/10.1056/NEJMoa0905561
  3. Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021 Mar;85:1-13.  https://doi.org/10.1016/j.ejim.2020.11.014
  4. Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf. 2017 Jun;16(6):673-685.  https://doi.org/10.1080/14740338.2017.1325870
  5. AlLehibi AH, Alsubaie FF, Alzahrani RH, et al. Clinical Presentations and Risk Factors of Gastrointestinal Bleeding in the Emergency Department: A Multicenter Retrospective Study. Cureus. 2024 May 8;16(5):e59912. https://doi.org/10.7759/cureus.59912
  6. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2017 Apr;152(5):1014-1022.e1.  https://doi.org/10.1053/j.gastro.2016.12.018
  7. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1674-1683.e3.  https://doi.org/10.1016/j.cgh.2017.04.031
  8. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015 Jan;175(1):18-24.  https://doi.org/10.1001/jamainternmed.2014.5398
  9. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176
  10. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. https://doi.org/10.1093/eurheartj/ehae177
  11. Ray WA, Chung CP, Murray KT, et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA. 2018 Dec 4;320(21):2221-2230. https://doi.org/10.1001/jama.2018.17242
  12. Kuvaev RO. Not sour! Non Nocere. New Therapeutic Journal. 2025;(4):80-86. (In Russ.)
  13. Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019 Aug;157(2):403-412.e5.  https://doi.org/10.1053/j.gastro.2019.04.041
  14. Maev I.V., Zaborovsky A.V., Yurenev G.L., et al. Efficacy and safety of pantoprazole in the treatment of patients with gastroesophageal reflux disease in real-life clinical practice: a multicenter observational study. Medical Council. 2025;19(8): 24–31.  https://doi.org/10.21518/ms2025-230
  15. Maev I.V., Zaborovsky A.V., Tararina L.A., et al. Efficacy and safety of pantoprazole in the treatment of patients with acid-related diseases in Russia: a multicenter observational study. Effective Pharmacotherapy. 2023;19(43):20–27.  https://doi.org/10.33978/2307-3586-2023-19-43-20-27
  16. Package leaflet – information for the consumer: Nolpaza®, 20 mg and 40 mg, enteric-coated tablets, film-coated [Electronic resource] / State Register of Medicines (date accessed: 02/05/2026). https://grls.minzdrav.gov.ru/InstrImg/2025/06/10/1518013/95f4e0e1-5332-43b2-9e2a-3829d8c696cd.pdf
  17. Results of a comparative analysis of instructions for use of drugs with the INN pantoprazole, registered in the State Register of Medicines as of 05.02.2026 (author’s own data).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.